



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Fang Chen

Serial No. 10/090,090

Filed: March 4, 2002

For: DNA MOLECULES ENCODING HUMAN NUCLEAR
RECEPTOR PROTEIN nNR7-1Art Unit: 1646

Examiner: _____

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention.

In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By J. Martland Date Sept. 12, 2003
REG. NO. 36,545

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

U. S. SERIAL NUMBER	RELATED APPLICATION	
	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

☐

the attached information is filed within three months of the filing date of the captioned case.

☒

the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.

☐

the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).

☐

the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

☐

the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: J. Mark Hand

Attorney For Applicant(s)

Reg. No. 36,545

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3905

Date: Sept. 12, 2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

2

of

3

COMPLETE IF KNOWN

Application Number	10/090,090
Filing Date	March 4, 2002
First Named Inventor	Fang Chen
Group Art Unit	
Examiner Name	
Attorney Docket Number	20084YCA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
AA		Bertilsson et al. 'Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction', Proc. Natl. Acad. Sci USA, Vol 95, pp 12208-12213 (Oct 1998)
AB		Baker et al. 'Cloning and expression of full-length cDNA encoding human vitamin D receptor', Proc. Natl. Acad. Sci, Vol 85, pp 3294-3298 (May 1988)
AC		Baes et al. 'A New Orphan Member of the Nuclear Hormone Receptor Superfamily that Interacts with a Subset of Retinoic Acid Response Elements', Molecular and Cellular Biology, Vol 14, No. 3 pp 1544-1552 (March 1994)
AD		Hollenberg et al. 'Primary structure and expression of a functional human glucocorticoid receptor cDNA', Nature Vol. 318 pp 635-641 (Dec 1985)
AE		Lubahn et al. 'The Human Androgen Receptor: Complementary Deoxiribonucleic Acid Cloning, Sequence Analysis and Gen Expression Prostate', Mol. Endo. Vol 2, No 12, pp 1266-1275 (1988)
AF		Mosselman et al. 'ER Beta: identificaiton and characterization of a novel human estrogen receptor', FEBS Letters 392, pp 49-53 (1996)
AG		Power et al., 'New insights into activation of the steroid hormone receptor superfamily', Trends in Pharm. Sci. 13: 318-323 (Aug. 1992)
AH		Tsai et al., 'Molecular Mechanisms of Action of Steroid/Thyroid Receptor Superfamily Members', Annu. Rev. Biochem. 63: 451-486 (1994)
AI		Tontonoz et al. 'Stimulation of Adipogenesis of Fibroblasts by PPAR 2, a Lipid-Activated Transcription Factor', Cell, Vol 79, pp 1147-1156, Dec 30, 1994
AJ		Lehmann et al. 'An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor Gamma (PPAR Gamma): The Jour. of Biol. Chem. Vol 270, No. 22 issue of June 2; pp 12953-12956, 1995.
AK		Mangelsdorf et al. 'The RXR Heterodimers and Orphan Receptors', Cell 83: 841-850 (1995)
AL		Teboul et al. 'Thiazolidinediones and Fatty Acids Convert Myogenic Cells in Adipose like Cells, The Jour. of Biol. Chem. Vol 270, No. 47, issue of November 24, pp 28183-28187 (1995)
AM		Lehman et al. 'The Human Orphan Nuclear Receptor PXR is Activated by Compounds that Regulate CYP3A4 Gene Expression and Cause Drug Interactions', J. Clinical Investigation 102: 1016-1023 (1998)
AN		Giguere et al. 'Identification of a New Class of Steroid Hormone Receptors', Nature Vol 331, No. 6151, Jan 7, 1998 pp 91-94
AO		Lehmann et al. 'Homo sapiens orphan nuclear receptor PR mRNA', Sept. 3, 1998; AC No: AF061056

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003